Avoro Capital Advisors LLC Avadel Pharmaceuticals PLC Transaction History

Avoro Capital Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $1.79 Million - $11.6 Million	-1,670,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $4.44 Million - $6.76 Million	-605,000 Reduced 26.59%	1,670,000 $13.5 Million
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $13.6 Million - $20.7 Million	-2,090,000 Reduced 47.88%	2,275,000 $22.3 Million
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $829,950 - $1.31 Million	165,000 Added 3.93%	4,365,000 $29.2 Million
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $1.84 Million - $3.28 Million	-365,655 Reduced 8.01%	4,200,000 $21.2 Million
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $1.45 Million - $2.35 Million	200,000 Added 4.58%	4,565,655 $36.9 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $17.7 Million - $46.5 Million	4,365,655 New	4,365,655 $34.7 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.